A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.
- Resource Type
- Article
- Source
- Menopause (10723714); Sep2023, Vol. 30 Issue 9, p940-946, 7p
- Subject
- Language
- ISSN
- 10723714